Antihypertensive Medication Classes and the Risk of Dementia: A Systematic Review and Network Meta-Analysis

Abstract

Objectives: To systematically review and synthesize the evidence on differential associations between antihypertensive medication (AHM) classes and the risk of incident dementia. Design: Systematic review and random effects frequentist network meta-analysis. Embase, MEDLINE, and the Cochrane library were searched from origin to December 2019. Setting and participants: Randomized controlled trials (RCTs) and prospective cohort studies that compared associations of different AHM classes with incident all-cause dementia and/or Alzheimer's disease over at least 1 year of follow-up. Measures: All cause dementia and/or Alzheimer's disease. Results: Fifteen observational studies and 7 RCTs were included. Data on AHM classes were available for 649,790 participants and dementia occurred in 19,600 (3.02%). Network meta-analysis showed that in observational studies, treatment with either calcium channel blockers (CCBs) or angiotensin II receptor blockers (ARBs) was associated with lower dementia risks than treatment with other antihypertensives: CCBs vs angiotensin converting enzyme inhibitors (ACE inhibitors) (HR¼0.84, 95% CI 0.74-0.95), beta blockers (HR¼0.83, 95% CI 0.73-0.95) and diuretics (HR¼0.89, 95% CI 0.78-1.01) and ARBs vs ACE inhibitors (HR¼0.88, 95% CI 0.81-0.97), beta blockers (HR¼0.87, 95% CI 0.77-0.99), and diuretics (HR¼0.93, 95% CI 0.83-1.05). There were insufficient RCTs to create a robust network based on randomized data alone. Conclusions and Implications: Recommending CCBs or ARBs as preferred first-line antihypertensive treatment may significantly reduce the risk of dementia. If corroborated in a randomized setting, these findings reflect a low-cost and scalable opportunity to reduce dementia incidence worldwide.

Safety and efficacy of losartan for the reduction of brain atrophy in clinically diagnosed Alzheimer's disease (the RADAR trial): a double-blind, randomised, placebo-controlled, phase 2 trial

“…Our randomised controlled trial does not support evidence from observational studies and a recent systematic review 29 that ARAs might offer preferential benefit over other forms of hypertension treatment regarding the incidence and progression of Alzheimer's disease. Other meta-analyses conclude that there are no such hypertension treatment differences over dementia incidence, 2 , 9 , 10 although those findings and others agree that hypertension management is protective.…”

Hypertension and Alzheimer's disease pathology at autopsy: A systematic review

“…Studies suggest that reducing BP (variability), influencing the renin-angiotensin system, and/or modulating intracellular calcium homeostasis, may protect against neural damage caused by vascular changes, increased blood-brain barrier permeability, inflammation, or ischemia, potentially through specific AHM class effects. [39][40][41][42][43][44] However, observational biases may also play a role. [39][40][41][42][43][44] Next to gold-standard neuropathological data, in vivo ADNCrelated biomarkers obtained from imaging and cerebrospinal fluid (CSF) may provide valuable context, because they allow investigating the relation between BP and ADNC during life, before the effects of old age and dementia.…”

Single-pill fixed-dose drug combinations to reduce blood pressure: the right pill for the right patient

“…Although previous studies have often shown inconsistent results, CCB and ARB likely had larger benefits than other antihypertensive drug classes on prevention of cognitive decline in meta-analysis of RCT and prospective cohort studies. 98 – 100 …”